ProteqFlu-Te

Country: European Union

Language: Italian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

Clostridium tetani tetanico / Vcp 2242 virus / Vcp1529 virus / Vcp1533 virus / vCP3011 virus

Available from:

Boehringer Ingelheim Vetmedica GmbH

ATC code:

QI05AI01

INN (International Name):

equine influenza (live recombinant) and tetanus vaccine

Therapeutic group:

Cavalli

Therapeutic area:

Immunologicals for equidae, Live viral and inactivated bacterial vaccines, equine influenza virus + clostridium

Therapeutic indications:

Immunizzazione attiva di cavalli di età pari o superiore a quattro mesi contro l'influenza equina per ridurre i segni clinici e l'escrezione di virus dopo l'infezione e contro il tetano per prevenire la mortalità.

Product summary:

Revision: 16

Authorization status:

autorizzato

Authorization date:

2003-03-06

Patient Information leaflet

                                13
B. FOGLIETTO ILLUSTRATIVO
14
FOGLIETTO ILLUSTRATIVO:
PROTEQFLU-TE SOSPENSIONE INIETTABILE PER CAVALLI
1.
NOME E INDIRIZZO DEL TITOLARE DELL’AUTORIZZAZIONE
ALL’IMMISSIONE IN COMMERCIO E DEL TITOLARE
DELL’AUTORIZZAZIONE ALLA PRODUZIONE RESPONSABILE DEL
RILASCIO DEI LOTTI DI FABBRICAZIONE, SE DIVERSI
Titolare dell’autorizzazione all’immissione in commercio:
Boehringer Ingelheim Vetmedica GmbH
55216 Ingelheim/Rhein
GERMANIA
Produttore responsabile del rilascio dei lotti di fabbricazione:
Boehringer Ingelheim Animal Health France SCS
Laboratoire Porte des Alpes
Rue de l’Aviation
F-69800 Saint Priest
Francia
2.
DENOMINAZIONE DEL MEDICINALE VETERINARIO
ProteqFlu-Te sospensione iniettabile per cavalli
3.
INDICAZIONE DEL(I) PRINCIPIO(I) ATTIVO(I) E DEGLI ALTRI INGREDIENTI
Una dose da 1 ml contiene:
PRINCIPI ATTIVI:
Virus del vaiolo del canarino (vCP2242), ricombinante per
influenza A/eq/Ohio/03 [H
3
N
8
]
...............................................................................
≥
5,3 log10 FAID
50
*
Virus del vaiolo del canarino (vCP3011), ricombinante per
influenza A/eq/Richmond/1/07 [H
3
N
8
]....................................................................
≥
5,3 log10 FAID
50
*
Anatossina di
_Clostridium tetani
...............................................................................................
_
≥
30 UI**
* contenuto in vCP determinato attraverso FAID
50
globale (dose infettante 50% determinata mediante
immunofluorescenza) e rapporto tra vCP attraverso qPCR.
** Titolo sierico dell’antitossina indotto dopo vaccinazioni
ripetute nella cavia secondo Ph. Eur.
ADIUVANTE:
Carbomero
………………………………………………………………………………………….4
mg
4.
INDICAZIONE(I)
Immunizzazione attiva dei cavalli di 4 mesi, o più, di età nei
confronti dell’influenza equina per
ridurre i sintomi clinici e l’escrezione dei virus in seguito ad
infezione, e nei confronti del tetano per
prevenirne la mortalità.
Instaurarsi dell’immunità: 14 giorni dop
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ALLEGATO I
RIASSUNTO DELLE CARATTERISTICHE DEL PRODOTTO
2
1.
DENOMINAZIONE DEL MEDICINALE VETERINARIO
ProteqFlu-Te sospensione iniettabile per cavalli
2.
COMPOSIZIONE QUALITATIVA E QUANTITATIVA
Una dose da 1 ml contiene:
PRINCIPI ATTIVI:
Virus del vaiolo del canarino (vCP2242), ricombinante per
influenza A/eq/Ohio/03 [H
3
N
8
]
...............................................................................
> 5,3 log10 FAID
50
*
Virus del vaiolo del canarino (vCP3011), ricombinante per
influenza A/eq/Richmond/1/07 [H
3
N
8
]....................................................................
> 5,3 log10 FAID
50
*
Anatossina di
_Clostridium tetani_
...............................................................................................
≥
30 UI**
* contenuto in vCP determinato attraverso FAID
50
globale (dose infettante 50% determinata mediante
immunofluorescenza) e rapporto tra vCP attraverso qPCR.
** Titolo sierico dell’antitossina dopo vaccinazioni ripetute nella
cavia secondo Ph. Eur.
ADIUVANTE:
Carbomero
.........................................................................................................................................
4 mg
Per l’elenco completo degli eccipienti, vedere paragrafo 6.1.
3.
FORMA FARMACEUTICA
Sospensione iniettabile.
4.
INFORMAZIONI CLINICHE
4.1
SPECIE DI DESTINAZIONE
Cavalli
4.2
INDICAZIONI PER L’UTILIZZAZIONE, SPECIFICANDO LE SPECIE DI
DESTINAZIONE
Immunizzazione attiva dei cavalli di 4 mesi, o più, di età nei
confronti dell’influenza equina per
ridurre i sintomi clinici e l’escrezione dei virus in seguito ad
infezione, e nei confronti del tetano per
prevenirne la mortalità.
Instaurarsi dell’immunità: 14 giorni dopo la vaccinazione di base.
Durata dell’immunità indotta dallo schema vaccinale:
-
5 mesi dopo la vaccinazione di base;
-
dopo la vaccinazione di base ed il richiamo 5 mesi dopo: 1 anno nei
confronti dell’influenza
equina e 2 anni nei confronti del tetano.
4.3
CONTROINDICAZIONI
Nessuna.
4.4
AVVERTENZE SPECIALI
Nessuna.
3
4.5
PRECAUZIO
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 03-09-2021
Summary of Product characteristics Summary of Product characteristics Bulgarian 03-09-2021
Public Assessment Report Public Assessment Report Bulgarian 13-11-2014
Patient Information leaflet Patient Information leaflet Spanish 03-09-2021
Public Assessment Report Public Assessment Report Spanish 13-11-2014
Patient Information leaflet Patient Information leaflet Czech 03-09-2021
Public Assessment Report Public Assessment Report Czech 13-11-2014
Patient Information leaflet Patient Information leaflet Danish 03-09-2021
Public Assessment Report Public Assessment Report Danish 13-11-2014
Patient Information leaflet Patient Information leaflet German 03-09-2021
Public Assessment Report Public Assessment Report German 13-11-2014
Patient Information leaflet Patient Information leaflet Estonian 03-09-2021
Public Assessment Report Public Assessment Report Estonian 13-11-2014
Patient Information leaflet Patient Information leaflet Greek 03-09-2021
Public Assessment Report Public Assessment Report Greek 13-11-2014
Patient Information leaflet Patient Information leaflet English 03-09-2021
Public Assessment Report Public Assessment Report English 13-11-2014
Patient Information leaflet Patient Information leaflet French 03-09-2021
Public Assessment Report Public Assessment Report French 13-11-2014
Patient Information leaflet Patient Information leaflet Latvian 03-09-2021
Public Assessment Report Public Assessment Report Latvian 13-11-2014
Patient Information leaflet Patient Information leaflet Lithuanian 03-09-2021
Summary of Product characteristics Summary of Product characteristics Lithuanian 03-09-2021
Public Assessment Report Public Assessment Report Lithuanian 13-11-2014
Patient Information leaflet Patient Information leaflet Hungarian 03-09-2021
Summary of Product characteristics Summary of Product characteristics Hungarian 03-09-2021
Public Assessment Report Public Assessment Report Hungarian 13-11-2014
Patient Information leaflet Patient Information leaflet Maltese 03-09-2021
Public Assessment Report Public Assessment Report Maltese 13-11-2014
Patient Information leaflet Patient Information leaflet Dutch 03-09-2021
Public Assessment Report Public Assessment Report Dutch 13-11-2014
Patient Information leaflet Patient Information leaflet Polish 03-09-2021
Public Assessment Report Public Assessment Report Polish 13-11-2014
Patient Information leaflet Patient Information leaflet Portuguese 03-09-2021
Summary of Product characteristics Summary of Product characteristics Portuguese 03-09-2021
Public Assessment Report Public Assessment Report Portuguese 13-11-2014
Patient Information leaflet Patient Information leaflet Romanian 03-09-2021
Public Assessment Report Public Assessment Report Romanian 13-11-2014
Patient Information leaflet Patient Information leaflet Slovak 03-09-2021
Public Assessment Report Public Assessment Report Slovak 13-11-2014
Patient Information leaflet Patient Information leaflet Slovenian 03-09-2021
Summary of Product characteristics Summary of Product characteristics Slovenian 03-09-2021
Public Assessment Report Public Assessment Report Slovenian 13-11-2014
Patient Information leaflet Patient Information leaflet Finnish 03-09-2021
Public Assessment Report Public Assessment Report Finnish 13-11-2014
Patient Information leaflet Patient Information leaflet Swedish 03-09-2021
Public Assessment Report Public Assessment Report Swedish 13-11-2014
Patient Information leaflet Patient Information leaflet Norwegian 03-09-2021
Summary of Product characteristics Summary of Product characteristics Norwegian 03-09-2021
Patient Information leaflet Patient Information leaflet Icelandic 03-09-2021
Summary of Product characteristics Summary of Product characteristics Icelandic 03-09-2021
Patient Information leaflet Patient Information leaflet Croatian 03-09-2021
Public Assessment Report Public Assessment Report Croatian 13-11-2014

View documents history